journal article·2023-07-10

Development and Characterization of Lactobacillus rhamnosus-Containing Bioprints for Application to Catheter-Associated Urinary Tract Infections

Anthony J. Kyser, Mohamed Y. Mahmoud, Nicholas T. Johnson, Bassam Fotouh, Jill M. Steinbach-Rankins, Nicole M. Gilbert, Hermann B. Frieboes

Publisher page

Abstract

Catheter-associated urinary tract infections (CAUTI) are a significant healthcare burden affecting millions of patients annually. CAUTI are characterized by infection of the bladder and pathogen colonization of the catheter surface, making them especially difficult to treat. Various catheter modifications have been employed to reduce pathogen colonization, including infusion of antibiotics and antimicrobial compounds, altering the surface architecture of the catheter, or coating it with nonpathogenic bacteria. Lactobacilli probiotics offer promise for a “bacterial interference” approach because they not only compete for adhesion to the catheter surface but also produce and secrete antimicrobial compounds effective against uropathogens. Three-dimensional (3D) bioprinting has enabled fabrication of well-defined, cell-laden architectures with tailored release of active agents, thereby offering a novel means for sustained probiotic delivery. Silicone has shown to be a promising biomaterial for catheter applications due to mechanical strength, biocompatibility, and its ability to mitigate encrustation on the catheter. Additionally, silicone, as a bioink, provides an optimum matrix for bioprinting lactobacilli. This study formulates and characterizes novel 3D-bioprinted Lactobacillus rhamnosus (L. rhamnosus)-containing silicone scaffolds for future urinary tract catheterization applications. Weight-to-weight (w/w) ratio of silicone/ L. rhamnosus was bioprinted and cured with relative catheter dimensions in diameter. Scaffolds were analyzed in vitro for mechanical integrity, recovery of L. rhamnosus, antimicrobial production, and antibacterial effect against uropathogenic Escherichia coli, the leading cause of CAUTI. The results show that L. rhamnosus -containing scaffolds are capable of sustained recovery of live bacteria over 14 days, with sustained production of lactic acid and hydrogen peroxide. Through the use of 3D bioprinting, this study presents a potential alternative strategy to incorporate probiotics into urinary catheters, with the ultimate goal of preventing and treating CAUTI.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Urinary Tract Infections Management · Gut microbiota and health · Enterobacteriaceae and Cronobacter Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Bioengineering, University of Louisville Speed School of Engineering, Louisville, Kentucky 40202, United States

Department of Toxicology and Forensic Medicine, Faculty of Veterinary Medicine, Cairo University, Giza 12613, Egypt

Kentucky Wesleyan College, Owensboro, Kentucky 42301, United States

Formerly at: Department of Bioengineering and Center for Predictive Medicine, University of Louisville Speed School of Engineering, Louisville, Kentucky 40202, United States

Department of Pediatrics, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri 63110, United States

Center for Women’s Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri 63110, United States

Center for Predictive Medicine, University of Louisville, Louisville, Kentucky 40202, United States

Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky 40202, United States

UofL Health─Brown Cancer Center, University of Louisville, Louisville, Kentucky 40202, United States

Funding

National Institute of Diabetes and Digestive and Kidney Diseases · National Institute of General Medical Sciences

References (61)

Show source-provided references
1. 10.3109/03091902.2015.108560010.3109/03091902.2015.1085600 ↗
2. 10.1001/jama.2017.1213710.1001/jama.2017.12137 ↗
3. 10.1177/175628721983217210.1177/1756287219832172 ↗
4. Thakur, V.; Sumant, O. Intermittent Catheter Market by Product (Uncoated Intermittent Catheter and Coated Intermittent Catheter), Indication (Urinary Incontinence, Surgery, Spinal Cord Injuries, and Others), Category (Male Length Catheter, Kids Length Catheter, and Female Length Catheter), and End User (Hospitals, Medical Research Centers, and Ambulatory Surgical Centers): Global Opportunity Analysis and Industry Forecast, 2021-2030, 2022.
5. 10.1086/65048210.1086/650482 ↗
6. 10.1038/nrurol.2010.19010.1038/nrurol.2010.190 ↗
7. 10.1310/sci2503-22810.1310/sci2503-228 ↗
8. 10.1007/s11908-001-0085-510.1007/s11908-001-0085-5 ↗
9. 10.1097/CCM.0b013e31820a858110.1097/CCM.0b013e31820a8581 ↗
10. 10.1086/65791210.1086/657912 ↗
11. 10.7860/JCDR/2016/20486.793910.7860/JCDR/2016/20486.7939 ↗
12. 10.1002/mabi.20180038410.1002/mabi.201800384 ↗
13. 10.1016/j.jinf.2015.05.01410.1016/j.jinf.2015.05.014 ↗
14. 10.3205/id00004610.3205/id000046 ↗
15. 10.1128/mBio.00218-2010.1128/mBio.00218-20 ↗
16. 10.1128/microbiolspec.UTI-0025-201610.1128/microbiolspec.UTI-0025-2016 ↗
17. 10.1093/infdis/jiaa76210.1093/infdis/jiaa762 ↗
18. 10.1038/s41591-019-0450-210.1038/s41591-019-0450-2 ↗
19. 10.3390/jcm1007146110.3390/jcm10071461 ↗
20. Cadieux P. A. · J. Physiol. Pharmacol. · 2009 · 60 · 13
21. 10.1080/10790268.2019.161645610.1080/10790268.2019.1616456 ↗
22. 10.1177/175628721987559410.1177/1756287219875594 ↗
23. 10.1002/pmrj.1247010.1002/pmrj.12470 ↗
24. 10.1186/1471-2180-12-1510.1186/1471-2180-12-15 ↗
25. 10.3920/BM2012.001110.3920/BM2012.0011 ↗
26. 10.3390/ijms2402132310.3390/ijms24021323 ↗
27. 10.1007/s10529-019-02694-210.1007/s10529-019-02694-2 ↗
28. 10.1111/j.1365-2672.2006.02857.x10.1111/j.1365-2672.2006.02857.x ↗
29. 10.1111/j.1574-6968.2006.00250.x10.1111/j.1574-6968.2006.00250.x ↗
30. 10.1097/MPG.0b013e3181924d1e10.1097/MPG.0b013e3181924d1e ↗
31. 10.1128/AEM.01393-0710.1128/AEM.01393-07 ↗
32. 10.1111/j.1574-695X.2010.00680.x10.1111/j.1574-695X.2010.00680.x ↗
33. 10.1128/msphere.00439-1910.1128/msphere.00439-19 ↗
34. 10.3390/polym1210217410.3390/polym12102174 ↗
35. 10.1063/1.343171510.1063/1.3431715 ↗
36. 10.1016/j.ijpx.2021.10009110.1016/j.ijpx.2021.100091 ↗
37. 10.1155/2015/18796110.1155/2015/187961 ↗
38. 10.2323/jgam.44.37110.2323/jgam.44.371 ↗
39. 10.1017/ice.2019.29610.1017/ice.2019.296 ↗
40. 10.1016/j.mehy.2018.03.00110.1016/j.mehy.2018.03.001 ↗
41. 10.1097/qco.000000000000022810.1097/qco.0000000000000228 ↗
42. 10.1155/2015/50102910.1155/2015/501029 ↗
43. 10.3390/microorganisms403003510.3390/microorganisms4030035 ↗
44. 10.1002/14651858.cd010723.pub10.1002/14651858.cd010723.pub ↗
45. 10.5152/tud.2018.4874210.5152/tud.2018.48742 ↗
46. Naderi A. · Iran J. Basic Med. Sci. · 2014 · 17 · 201
47. 10.1016/j.clinthera.2008.03.01310.1016/j.clinthera.2008.03.013 ↗
48. 10.2165/00003495-200666090-0000710.2165/00003495-200666090-00007 ↗
49. 10.1016/j.ijpharm.2021.12050110.1016/j.ijpharm.2021.120501 ↗
50. 10.1016/j.compositesa.2018.09.00810.1016/j.compositesa.2018.09.008 ↗
51. 10.1021/acsami.0c1820110.1021/acsami.0c18201 ↗
52. 10.1106/NCRR-MDV5-FQFG-L7PG10.1106/NCRR-MDV5-FQFG-L7PG ↗
53. 10.1089/end.2010.059110.1089/end.2010.0591 ↗
54. 10.1186/s40824-021-00235-510.1186/s40824-021-00235-5 ↗
55. 10.1016/j.fhfh.2022.10008810.1016/j.fhfh.2022.100088 ↗
56. 10.1099/jmm.0.05155-010.1099/jmm.0.05155-0 ↗
57. 10.1111/j.1574-6968.2009.01887.x10.1111/j.1574-6968.2009.01887.x ↗
58. 10.1007/s12010-019-03031-z10.1007/s12010-019-03031-z ↗
59. 10.4103/0255-0857.3885310.4103/0255-0857.38853 ↗
60. 10.1093/gbe/evw12310.1093/gbe/evw123 ↗
61. 10.3791/52892-v10.3791/52892-v ↗